to play blackjack
to play blackjack
to play blackjack
, /PRNewswire/ -- Wingstop Inc. (NASDAQ: WING) today announced that its board of directors approved the purchase of up to an additional of its outstanding shares of common stock under its existing share repurchase program, effective immediately. This repurchase program follows the substantial completion of purchases of common stock under the inaugural repurchase authorization from . With this additional repurchase authorization, the Company anticipates executing a accelerated share repurchase ("ASR") program that will commence in the fourth quarter of 2024. "We believe our asset-lite, highly-franchised model enables industry-leading shareholder returns," commented , Chief Financial Officer. "Since becoming a public company in 2015, we have returned more than of capital to shareholders. Our share repurchase program is another example of the long-term value creation enabled by our category of one operating model." Repurchases under the program may be made in the open market, in privately negotiated transactions or by other means, including through trading plans intended to qualify under Rule 10b5-1 of the Securities and Exchange Act of 1934 and accelerated share repurchase agreements, with the amount and timing of repurchases to be determined at Wingstop's discretion, depending on market and business conditions, prevailing stock prices, and contractual limitations, among other factors. Open market repurchases will be structured to occur in accordance with applicable federal securities laws. This program does not obligate Wingstop to acquire any particular amount of common stock, or at any specific time or intervals and may be modified, suspended or terminated at any time at Wingstop's discretion. Wingstop expects to fund repurchases with existing cash and cash equivalents, including the proceeds from its recently completed financing transaction which closed on . Founded in 1994 and headquartered in , Wingstop Inc. (NASDAQ: WING) operates and franchises more than 2,450 locations worldwide. The Wing Experts are dedicated to Serving the World Flavor through an unparalleled guest experience and a best-in-class technology platform, all while offering classic and boneless wings, tenders, and chicken sandwiches, cooked to order and hand sauced-and-tossed in fans' choice of 12 bold, distinctive flavors. Wingstop's menu also features signature sides including fresh-cut, seasoned fries and freshly-made ranch and bleu cheese dips. In fiscal year 2023, Wingstop's system-wide sales increased 27.1% to approximately , marking the 20th consecutive year of same store sales growth. With a vision of becoming a Top 10 Global Restaurant Brand, Wingstop's system is comprised of corporate-owned restaurants and independent franchisees, or brand partners, who account for approximately 98% of Wingstop's total restaurant count of 2,458 as of . A key to this business success and consumer fandom stems from The Wingstop Way, which includes a core value system of being Authentic, Entrepreneurial, Service-minded, and Fun. The Wingstop Way extends to the brand's environmental, social and governance platform as Wingstop seeks to provide value to all guests. In 2023, Wingstop earned its "Best Places to Work" certification. The Company landed on Entrepreneur Magazine's "Fastest-Growing Franchises" list and ranked #16 on "Franchise 500." Wingstop was listed on Technomic's "Top 500 Chain Restaurant Report," QSR Magazine's "2023 QSR 50" and Franchise Time's "40 Smartest-Growing Franchises." For more information, visit or and follow @Wingstop on X, Instagram, Facebook, and TikTok. Learn more about Wingstop's involvement in its local communities at . Unless specifically noted otherwise, references to our website addresses, the website addresses of third parties or other references to online content in this press release do not constitute incorporation by reference of the information contained on such website and should not be considered part of this release. This news release includes statements of our expectations, intentions, plans and beliefs that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to come within the safe harbor protection provided by those sections. These statements, which involve risks and uncertainties, relate to the discussion of our expectations concerning the implementation and execution of our share repurchase program, including the anticipated execution of a ASR and our strategic growth initiatives. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "may," "will," "should," "expect," "intend," "plan," "outlook," "guidance," "anticipate," "believe," "think," "estimate," "seek," "predict," "can," "could," "project," "potential" or, in each case, their negative or other variations or comparable terminology, although not all forward-looking statements are accompanied by such terms. These forward-looking statements are made based on expectations and beliefs concerning future events affecting us and are subject to uncertainties, risks, and factors relating to our operations and business environments, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by these forward-looking statements. Please refer to the risk factors discussed in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which can be found at the SEC's website . The discussion of these risks is specifically incorporated by reference into this news release. When considering forward-looking statements in this news release or that we make in other reports or statements, you should keep in mind the cautionary statements in this news release and future reports we file with the SEC. New risks and uncertainties arise from time to time, and we cannot predict when they may arise or how they may affect us. Any forward-looking statement in this news release speaks only as of the date on which it was made. Except as required by law, we assume no obligation to update or revise any forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future. View original content to download multimedia: SOURCE Wingstop Restaurants Inc.7.0 earthquake off Northern California prompts brief tsunami warningORCHARD PARK, N.Y. — In losing Sunday’s battle with the Buffalo Bills, perhaps the best team in football, Jerod Mayo won the war. Best I can tell, he’s staying put. For 2025, and maybe beyond. To his angry fan base and incredulous pockets of the New England Patriots’ media corps, remember Mayo’s future doesn’t hinge on winning this season. It’s not about what you want, or what I think. It’s about the Krafts, who hand-picked Mayo to succeed Bill Belichick four and a half years before he actually did, believing in him, and finding reasons to maintain that belief. In the eyes of someone who wants to believe, Sunday supplied enough reason. The Patriots led at halftime, then lost by three as 14-point underdogs. They became the first team since mid-October to hold the Bills under 30 points. Drake Maye outplayed the next MVP of the league for most of the game and took another step toward his destiny as a franchise quarterback, If that sounds like a low bar, that’s because it is. Such is life in Year 1 of a rebuild, a multi-year process ownership has committed to seeing through to the end with their organizational pillars now in place: Mayo, Maye and de facto GM Eliot Wolf. As frustrating as this 3-12 campaign has been, there are always nuggets of optimism amid the rubble of a losing season; particularly if you want to find them. The Krafts do, and so does Maye, who loves his head coach, by the way; calling questions about Mayo’s job security “BS.” “We’ve got his back,” Maye said post-game. Maye’s voice matters. Certainly more than any number of fans or media members. Ever since media-fueled speculation that Mayo could get canned at the end of his first season began rising, the caveat has always been the same: if, a Gillette Stadium-sized “if,” the Patriots bomb atomically down the stretch, ownership could pull the plug on Mayo. NFL Network insider Ian Rapoport became the latest to join that chorus Sunday with this pregame report: “The Krafts want to keep Jerod Mayo,” he said. “They believe he is the leader for the organization for the future, and they knew it would be a multi-year process to get this thing right. Now if things go off the rails, if they really start to struggle and he loses the locker room the last couple games of the season, we’ve seen this thing turn. “But as of now, the Patriots believe Jerod Mayo is their leader for the future.” Well, Mayo hasn’t lost the locker room. That’s a fact. To a man, both in public and from those I’ve spoken to in private, Patriots players believe in their head coach. Mayo might be a players’ coach, yes, in the best and worst senses. But the Patriots were a few plays away Sunday from pulling off their largest upset since Super Bowl XXXVI. “I think we’re building something good,” Maye said. The Patriots also played their best half of football this season against their toughest opponent yet. Another fact. Now, to the frustrated, I am with you. To the shocked, I understand. But to the trigger-happy, lay down your arms. Mayo, by all accounts, is returning in 2025. Alex Van Pelt, however, is another story. In the same vein that the Krafts could have viewed Sunday’s performance as a reason to save Mayo — despite his pathetic punt at midfield, down 10 with just eight and a half minutes left — they could have convinced themselves their offensive coordinator is the real problem. After all, team president Jonathan Kraft was visibly exasperated over Van Pelt’s play-calling during the Pats’ loss at Arizona a week earlier. Four days later, Van Pelt told reporters he had yet to hear from his boss. Well, that time may be coming. Trailing by three in the fourth quarter Sunday, Van Pelt called a pass that resulted in an unnecessary lateral and game-winning touchdown for Buffalo. His offense later operated like it was taking a Sunday drive with the game on the line, using up 3:16 of the final 4:19 en route to its final touchdown. Van Pelt, finally, weaponized Maye’s legs in critical situations, something that arguably should have been done weeks ago. Not to mention, Van Pelt’s top running back can’t stop fumbling, and the offensive line remains a hot mess. Call him Alex Van Fall Guy. Because Van Pelt’s offense, for the first time in a while, under-performed relative to Mayo’s defense. On merit, he deserves to stay; a case that’s harder to make for defensive coordinator DeMarcus Covington. But it’s not about merit this season. It’s not about what you want. It’s not about what I think. It’s about the Krafts; what they see, what they want, what they believe. Even in defeat. ____
The biopharma industry is a dynamic environment. To succeed in it and thrive, companies must be innovative and must constantly re-evaluate their strategies. This will help them to navigate the challenges of drug development and entry into the market. This article provides winning strategies that can help biopharma companies stay ahead of the curve. Performing clinical trials on new drugs and making them available to patients is long, complex, and capital-demanding. To increase your chances of clinical success with a new drug pipeline, your Research and Development (R&D) efforts must be collaborative, streamlined, and effective. Invest in the R&D pipeline to maximize your organization’s opportunities for innovative therapies and minimize your risks. This might require collaboration with biotech startups, technology providers, and academic institutions to help expand your capabilities. One way that biopharma companies can boost patient’s access to investigational medication is through the use of an expanded access program. Through an Early Access Care program, biopharma companies can better understand local regulatory compassionate use pathways and new FDA legislations pertaining to investigational drugs. Such programs often work with doctors directly, helping them understand all the documentation requirements for obtaining investigational medications for patients who are not responding to conventional treatments, expediting the entire process. When a broader population of patients receives promising therapies before full approval, there is a higher potential for developing real-world data, ultimately accelerating adoption. One strategy leaders in the biopharma industry use to stay ahead of the curve is advanced data analytics and AI. Advanced analytics help deliver valuable insights by identifying biochemical pathways and technologies that could attract investor and scientific attention even before preclinical evidence is available. Biopharma companies obtain data from numerous sources, including those from clinical trials, surveys that gather patient feedback, sales data, online forums, and social media that help them better understand public sentiments. This helps them harness real-world data to predict market trends, streamline drug discovery, and optimize clinical trials, ultimately lowering development costs and improving patient outcomes. Scouting and ranking investment options using AI and advanced analytics do not replace the conventional ways of nurturing relationships through collaborations. So, you must be open to forming alliances with other leaders in the industry, healthcare providers, and contract research organizations. This creates the opportunity for sharing expertise, resources, and risks. Using advanced analytics, you can augment your approaches and widen your geographic net. To maximize the value of external assets and partnerships, you need to adopt an activist approach. Track your internal and external assets using the same rigor and evaluation metrics. Such metrics include the level of evidence, value to patients, enrollment rates, and the timely completion of trials. Doing this ensures a level playing ground when making investment decisions. Not only does this help you maximize your company’s assets, but it also helps you decide which assets to progress. To stay competitive in the biopharma industry, you must invest in workforce development and address any skill gaps promptly. This ensures that your employees are knowledgeable enough to operate innovative digital technologies emerging in their fields, promoting automation in your company’s operations. Companies that invest in reskilling their workforce can retain top talent and their business advantage while fulfilling their obligations to their employees. In addition to providing growth opportunities for your workforce, ensure that your company culture promotes diversity and innovation. Investors don’t just look at the products that are offered to them. They also look at who is offering those opportunities to them. To boost investor confidence in your company, create a credible and strong team and emphasize your track record of success and ability to steer the organization towards success. Your approach should strategically combine expert insights, transparency , and simplicity. Break down scientific jargon into easily understandable terms, showcase your strong management team, and engage with expert consultants in the field to help you build sustainable relationships with investors. Use graphics and other pictorial illustrations when showcasing your solutions to potential investors. As a biopharma company, your products must meet high safety and efficacy standards. Ensure compliance in the dynamic regulatory landscape and stay ahead of your competitors by staying updated on evolving regulations that affect your industry. Having regulatory expertise helps you streamline your development processes and effectively bring your products to the market. Ensure you engage with regulatory agencies early during your drug development process to clarify expectations and receive guidance to help you align your approach to clinical trials and submissions for approval.Personal Cloud Market: $90.27B in 2022, Expected to Surpass $2704B by 2031
